Atsushi Terakubo, MD
Interventional Cardiology · Honolulu, HINPI 1285791343
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,903 of the $19,740 with a category attached, or 60.3%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.1%. 2025 is the largest year on record at $7,683, 4.2 times the $1,813 reported in 2019.
Across 374 payments — averaging $52.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$4K
- Abbott$3K
- Shockwave Medical, Inc$3K
- E.r. Squibb & Sons, L.L.C.$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Boston Scientific$972
- plus $6K from 21 others
What the payments were for
- Travel & lodging$7,83040%
- Food & beverage$11,90360%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 14 | $4,356 |
| Abbott | 13 | $2,956 |
| Shockwave Medical, Inc | 11 | $2,770 |
| E.r. Squibb & Sons, L.L.C. | 44 | $1,566 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $1,257 |
| Boston Scientific | 14 | $972 |
| Boehringer Ingelheim | 32 | $877 |
| AstraZeneca | 26 | $790 |
| Amgen | 28 | $681 |
| Novartis | 47 | $612 |
| Amarin Pharma, Inc. | 24 | $575 |
| Johnson & Johnson | 42 | $573 |
| Merck | 17 | $424 |
| Medtronic(2 entities) | 3 | $367 |
| Regeneron | 2 | $208 |
| Pfizer | 13 | $203 |
| Baxter Healthcare | 4 | $170 |
| Janssen Scientific Affairs, LLC | 1 | $136 |
| Bayer | 4 | $79 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $27 |
| Gilead | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Cvrx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,089
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$2,489
- Dragonfly OCT$1,097
- DRAGONFLY OPSTAR$1,094
- LifeVest$734
- CAMZYOS$535
- ELIQUIS$352
- XIENCE SIERRA$236
- Claria MRI$235
- Watchman$194
- WATCHMAN FLX$175
- MitraClip$170
- RUBY Coil$148
- JARDIANCE$139
- XARELTO$136
- AURORA EV-ICD MRI SURESCAN$132
- Repatha$125
- PRALUENT$114
- RESONATE$114
How this compares
Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 352 | $524,458 |
| EntrestoSacubitril/Valsartan | 108 | $171,015 |
| XareltoRivaroxaban | 107 | $142,974 |
| Repatha SureclickEvolocumab | 68 | $60,280 |
| VascepaIcosapent Ethyl | 56 | $47,602 |
| JardianceEmpagliflozin | 24 | $39,701 |
| Repatha PushtronexEvolocumab | 41 | $28,303 |
| Atorvastatin Calcium | 432 | $12,178 |
| BrilintaTicagrelor | 13 | $10,618 |
| Carvedilol ErCarvedilol Phosphate | 22 | $9,573 |
| Metoprolol Succinate | 421 | $8,220 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $4,967 |
| Ezetimibe | 74 | $4,132 |
| Carvedilol | 385 | $3,975 |
| Digoxin | 113 | $3,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $203 | $524,458352 claims |
| NovartisEntresto | $612 | $171,015108 claims |
| Johnson & JohnsonXarelto | $573 | $142,974107 claims |
| Boehringer IngelheimJardiance | $877 | $39,70124 claims |
| AstraZenecaBrilinta | $790 | $10,61813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Honolulu
- John CoganHonolulu$82K
- Kris KawamotoHonolulu$25K
- Giselle Baquero CaranamaHonolulu$20K
- Kelly PaschkeHonolulu$7K
- John KaoHonolulu$6K
- John O'MaraHonolulu$5K
- Brandon KaiHonolulu$3K
- Jay GadgilHonolulu$2K
- Marie NguyenHonolulu$189
- Jason CallWailuku$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.